Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No.324, Jingwu Road, Jinan, Shandong, 250021, People's Republic of China.
Biol Direct. 2019 Nov 27;14(1):23. doi: 10.1186/s13062-019-0255-8.
Patients diagnosed as diffuse large B cell lymphoma (DLBCL) with CD5 positive normally have a worse outcome and poorly respond to the regulatory treatment strategy.
We recently reported differently expressed tRFs and their potential target-genes of tRFs in patients with CD5+ R/R DLBCL. Differently expressed tRFs were detected by Illumina NextSeq instrument and the results were verified by quantitative real-time reverse transcription-PCR. tRF2Cancer database was searched to compared with the results. Further research was performed through bio-informatic analysis including gene ontology (GO) and pathway enrichment analyses, etc. A total of 308 tRFs were identified. Two sequences (AS-tDR-008946, AS-tDR-013492) were chosen for further investigated.
The results of Bioinformatics analysis revealed that the target genes including NEDD4L and UBA52 and several associated pathways including PI3K/AKT and MAPK/ERK might be involved in the development of CD5+ R/R DLBCL. Our preliminary study on the associated tRFs might provide a valuable measure to explore the pathogenesis and progression of CD5+ R/R DLBCL.
This article was reviewed by Zhen Qing Ye, Nagarajan Raju and Jin Zhuang Dou.
CD5 阳性弥漫性大 B 细胞淋巴瘤（DLBCL）患者的预后通常较差，对调节治疗策略的反应不佳。
我们最近报道了 CD5+R/R DLBCL 患者中差异表达的 tRFs 及其潜在的 tRFs 靶基因。通过 Illumina NextSeq 仪器检测差异表达的 tRFs，并通过定量实时逆转录-PCR 进行验证。在 tRF2Cancer 数据库中进行了比较。通过包括基因本体论（GO）和途径富集分析等生物信息学分析进一步研究。共鉴定出 308 个 tRFs。选择了两个序列（AS-tDR-008946、AS-tDR-013492）进行进一步研究。
生物信息学分析结果表明，靶基因包括 NEDD4L 和 UBA52，以及几个相关途径，包括 PI3K/AKT 和 MAPK/ERK，可能参与了 CD5+R/R DLBCL 的发生发展。我们对相关 tRFs 的初步研究可能为探索 CD5+R/R DLBCL 的发病机制和进展提供了有价值的方法。
叶振清、Raju Nagarajan 和 窦金庄。
